
CTAD 2026 Preview: Clinical Trial Updates and Emerging Alzheimer Disease Research
NeurologyLive's Louie Pasculli previews key clinical trial readouts, long-term treatment data, and emerging therapeutic approaches in Alzheimer disease ahead of CTAD 2026, held November 16-19 in Boston, Massachusetts. [WATCH TIME: 4 MINUTES]
With the 19th
In this video, NeurologyLive's Louie Pasculli previews several key clinical trial updates and emerging research that clinicians could be on the lookout for during this year's meeting. The preview offers an overview of the research landscape heading into the conference and several developments that may help shape ongoing discussions around AD treatment and clinical research.
WATCH TIME: 4 minutes | Captions are auto-generated and may contain errors.
This video explores several areas of
NeurologyLive will provide coverage throughout CTAD 2026, featuring updates on key research findings and clinical perspectives on developments across the AD research landscape. Coverage will include interviews with investigators and experts, along with reports highlighting notable data and discussions from the meeting.
Video Chapters:
- 00:00 – Introduction and CTAD 2026 overview
- 00:50 – Key clinical trial readouts: POLARIS-AD, PRImus-AD, and NTRX-07
- 02:01 – Long-term treatment data: Clarity AD, LEADER, and CELIA
- 02:57 – Emerging therapeutic approaches: trontinemab and posdinemab
- 03:28 – Biomarkers, artificial intelligence, and clinical trial design
- 03:58 – Closing and continued CTAD 2026 coverage
Related to this article








